Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Primary biliary cirrhosis (PBC) is a progressive cholestatic liver disease frequently leading to development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC. Improvement in some histological features, but not in histological stage, has been reported after 2 years of UDCA therapy. Thus, longer follow–up may be necessary to determine whether UDCA has a favorable effect on histological stage of disease and progression to cirrhosis. Our aim was to determine the long–term effects of UDCA therapy on histological stage and progression to cirrhosis in patients with PBC. Sixteen unselected patients with noncirrhotic PBC who had been on long–term UDCA therapy (13–15 mg/kg/d) for 6.6 ± 0.4 years (range, 5–9 years) were identified and their histological finding during treatment compared with that of 51 noncirrhotic patients with PBC who had received ineffective therapy (d–penicillamine [DPCA] or placebo) for 5.6 ± 0.07 years (range, 5–8 years). Histological stage was determined using the Ludwig classification. The rate of progression to cirrhosis (stage 4) was significantly less in the UDCA group than in the control group (13% vs. 49%P= .009). Although the overall rate of progression of histological stage was less in the UDCA group than in the control group (50% vs. 71%), this difference was not significant (P= .1). A marked improvement in liver biochemistries and Mayo risk score was noted in all patients during UDCA therapy; however, this improvement was not significantly different between patients who progressed and those who did not. In conclusion, long–term UDCA therapy appeared to delay the development of cirrhosis in PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationKaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
COMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228
Self-citationAngulo, P., Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M., Kamath, P. S., & Dickson, E. R. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00020.x · Cited by 203
Self-citationTime course of histological progression in primary biliary cirrhosis
Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D. (1996) · Hepatology · doi:10.1002/hep.510230108 · Cited by 184
Self-citationUrsodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis
Lindor, K. D., Jorgensen, R. A., Therneau, T. M., Malinchoc, M., & Dickson, E. R. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.12.1137 · Cited by 166
Self-citationTrial of Penicillamine in Advanced Primary Biliary Cirrhosis
Dickson, E. R., Fleming, T. R., Wiesner, R. H., Baldus, W. P., Fleming, C. R., Ludwig, J., & McCall, J. T. (1985) · New England Journal of Medicine · doi:10.1056/nejm198504183121602 · Cited by 165
Kaplan, M. M., DeLellis, R. A., & Wolfe, H. J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-9-199705010-00002 · Cited by 130
Vuoristo, M., Färkkilä, M. A., Karvonen, A., Leino, R., Lehtola, J., Mäkinen, J., Mattila, J. J., Friman, C., Seppälä, K., Tuominen, J., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90696-7 · Cited by 120
Lindor, K. D., Dickson, R. E., Jorgensen, R. A., Anderson, M. L., Wiesner, R. H., Gores, G. J., Lange, S. M., Rossi, S. S., Hofmann, A. F., & Baldus, W. P. (1995) · Hepatology · doi:10.1016/0270-9139(95)90624-x · Cited by 99
Self-citationKilmurry, M. R., Heathcote, E. J., Cauch-Dudek, K., O’Rourke, K., Bailey, R. J., Blendis, L. M., Ghent, C. N., Minuk, G. Y., Pappas, S. C., Scully, L. J., et al. (1996) · Hepatology · doi:10.1002/hep.510230532 · Cited by 94
Leuschner, U., Güldütuna, S., Imhof, M., Hübner, K., Benjaminov, A., & Leuschner, M. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80111-8 · Cited by 47
Batts, K. P., Jorgensen, R. A., Dickson, E. R., & Lindor, K. D. (1996) · PubMed · Cited by 37
Self-citationManagement of Primary Biliary Cirrhosis and Autoimmune Cholangitis
Angulo, P., & Lindor, K. D. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70011-8 · Cited by 14
Self-citationMatsuzaki, Y., Doy, M., Tanaka, N., Shoda, J., Osuga, T., Nakano, M., & Aikawa, T. (1994) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199401000-00010 · Cited by 10
In vitro assessment of fibrosis; Effect of UDCA in PBC patients*1
Peterson, T. C. (1993) · Hepatology · doi:10.1016/0270-9139(93)92345-z · Cited by 2
Heathcote, J. E., Cauch-Dudek, K., Walker, V., Bailey, R. J., Blendis, L. M., Ghent, C. N., Michieletti, P., Minuk, G. Y., Pappas, C. S., Scully, L. J., et al. (1994) · Hepatology · doi:10.1002/hep.1840190512 · Cited by 2
Research works printed but not linked: 7
- Combes, 1995, Hepatology, 22, 759
- Emmond, 1996, Hepatology, 24, 168a
- Dickson, 1989, 10 Hepatology, 97, 1
- Kilmurry, 1996, Hepatology, 23, 1148
- Batts, 1996, Am J Gastroenterol, 91, 2314
- Lindor, 1995, Hepatology, 22, 1158
- Kaplan, 1987, Adv Inten Med, 32, 359
Cited by
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
“[128] AnguloP,BattsKP,TherneauTM,JorgensenRA,DicksonER,Lindor KD.”
Background(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“Several randomized trials, combined analyses, and long-term observational studies have shown that UDCA not only improves biochemical indices but also delays histologic progression and improves survival without transplantation.(53,56-67) Accordingly, UDCA is the initial drug of choice for PBC therapy.”
BackgroundResultSelf-citationParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Metadata
- Authors
- Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Hepatology
- Published
- 1999-03
- Volume
- 29
- Issue
- 3
- Pages
- 644-647
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1993958712
- Cited by
- 234
- References
- 24
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 10 · 2021: 2 · 2020: 5 · 2019: 11 · 2018: 15 · 2017: 12 · 2016: 7 · 2015: 12 · 2014: 7 · 2013: 7 · 2012: 10
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6028 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, histological progression, long-term treatment, Ludwig classification, D-penicillamine, Mayo risk score, cholestatic liver disease, liver histopathology
- MeSH terms
- Adult, Aged, Cholagogues and Choleretics, Female, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Middle Aged, Penicillamine, Time Factors, Ursodeoxycholic Acid, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.